Self-sizing Radiofrequency Ablation balloonfor eradication of Barrett’s esophagus: arandomized trial comparing three differenttreatment regimens
Ontology highlight
ABSTRACT: Interventions: Circumferential radiofrequency ablation of Barrett’s
esophagus with the Self-sizing RFA balloon.
Inspection of the Barrett’s segment and randomization
The esophagus is evaluated using white light high-resolution
endoscopy (WLE) and narrow band imaging (NBI). The
extent of columnar lined esophagus is documented according
to the Prague C&M classification15 and by taking still images
with WLE+NBI at 1 cm intervals. In the absence of visible
abnormalities and no severe stenosis, patients are
subsequently randomized to circumferential ablation with the
Self Sizing RFA balloon using the simplified or the standard
ablation regiment.
Patients will be blinded for the administered treatment
regimen.
Standard ablation regimen
After mapping and randomization, the Barrett’s segment is
flushed with the mucolytic agent acetylcysteine (1%)
followed by flushing with tap water. The Self Sizing RFA
balloon (GI Solutions Covidien, Sunnyvale, CA) is then
introduced and positioned at the desired treatment zone. The
device is inflated, and the electrode unfurls until the
electrode contacts the esophageal wall. Under visual control
the BE is ablated (12 J/cm2 at 300 Watt) working proximal
to distal using visual repositioning. A small overlap (i.e.
<1cm) between ablation zones is allowed. After the first
ablation pass, the endoscope is removed followed by removal
of the ablation catheter. The coagulum is cleaned off the
balloon catheter. The endoscope is reintroduced to irrigate
and suction the ablation zone. A distal attachment cap may
be attached to the tip of the endoscope to gently wipe of the
coagulum from the ablated segment. After irrigating and
suctioning the debris away as much as possible, the Self
Sizing RFA RCT November 2014 vs 1 Page 10 van 16
ablat
Primary outcome:
Percentage of endoscopically visual surface regression of BE epithelium at 3 months, as scored
by two independent endoscopists blinded to the treatment regimen.
Study Design: Randomized controlled trial, Double blinded (masking used), Active, Parallel
DISEASE(S): Barrett's Esophagus, Barrett's Neoplasia, Barrett's Dysplasia, Radiofrequency Ablation, Intestinal Metaplasia
PROVIDER: 19450 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA